Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

Slides:

Advertisements

Similar presentations

Volume 61, Issue 5, Pages (May 2012)

Advertisements

Volume 68, Issue 6, Pages (December 2015)

Volume 61, Issue 3, Pages (March 2012)

Volume 62, Issue 3, Pages (September 2012)

Volume 155, Issue 3, Pages (March 1996)

Volume 50, Issue 3, Pages (September 2006)

Philipp Dahm, Ari D. Silverstein, Alon Z

The PSA Era is not Over for Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 62, Issue 2, Pages (August 2012)

Volume 69, Issue 4, Pages (April 2016)

Volume 62, Issue 4, Pages (October 2012)

Testosterone Therapy in Men With Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 1, Pages (July 2016)

The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients

Volume 49, Issue 2, Pages (February 2006)

Volume 51, Issue 6, Pages (June 2007)

Volume 69, Issue 1, Pages (January 2016)

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

Volume 71, Issue 3, Pages (March 2017)

Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis Sebastiano Nazzani, Felix Preisser, Marco Bandini, Michele Marchioni,

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 6, Pages (June 2013)

Volume 69, Issue 4, Pages (April 2016)

Volume 68, Issue 5, Pages (November 2015)

Volume 67, Issue 2, Pages (February 2015)

Prostate Cancer Detection: A View of the Future

Volume 62, Issue 2, Pages (August 2012)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

European Urology Oncology

Volume 71, Issue 6, Pages (June 2017)

Volume 73, Issue 4, Pages (April 2018)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Volume 53, Issue 4, Pages (April 2008)

Volume 63, Issue 3, Pages (March 2013)

Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery

Volume 59, Issue 1, Pages (January 2011)

Volume 60, Issue 6, Pages (December 2011)

Volume 68, Issue 4, Pages (October 2015)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective,

European Urology Oncology

Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study Oskar Bergengren, Hans Garmo, Ola Bratt, Lars Holmberg,

Prostate Cancer Nomograms: An Update

Volume 49, Issue 6, Pages (June 2006)

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

European Urology Oncology

European Urology Oncology

European Urology is “Your” Journal

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 50, Issue 5, Pages (November 2006)

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.

Fernando P. Secin, Fernando J. Bianco, Nicholas T

European Urology Oncology

Oncoforum Urology: Prostate Cancer 2008 at a Glance

European Urology Oncology

Axel Heidenreich European Urology Supplements

Salvage Local Treatments After Focal Therapy for Prostate Cancer

European Urology Oncology

Presentation transcript:

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano Nazzani, Marco Bandini, Zhe Tian, Fred Saad, Raisa S. Pompe, Alberto Briganti, Lars Budäus, Francesco Montorsi, Hartwig Huland, Markus Graefen, Derya Tilki, Pierre I. Karakiewicz European Urology Oncology Volume 1, Issue 2, Pages 160-168 (June 2018) DOI: 10.1016/j.euo.2018.03.006 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Flow diagram showing patient inclusion and exclusion. PSA=prostate-specific antigen. European Urology Oncology 2018 1, 160-168DOI: (10.1016/j.euo.2018.03.006) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Rate of non–organ-confined prostate cancer (A) unadjusted and (B) adjusted for clinical stage and biopsy Gleason grade group according to the year of diagnosis among patients with clinically localized prostate cancer treated with radical prostatectomy. EAPC=estimated annual percent change; CI=confidence interval. European Urology Oncology 2018 1, 160-168DOI: (10.1016/j.euo.2018.03.006) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Rate of pathologic primary Gleason ≥4 cancer (A) unadjusted and (B) adjusted for clinical stage and biopsy Gleason grade group according to the year of diagnosis among patients with clinically localized prostate cancer treated with radical prostatectomy. EAPC=estimated annual percent change; CI=confidence interval. European Urology Oncology 2018 1, 160-168DOI: (10.1016/j.euo.2018.03.006) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 4 Rate of non–organ-confined prostate cancer and/or primary Gleason ≥4 cancer (A) unadjusted and (B) adjusted for clinical stage and biopsy Gleason grade group according to the year of diagnosis among patients with clinically localized prostate cancer treated with radical prostatectomy. EAPC=estimated annual percent change; CI=confidence interval. European Urology Oncology 2018 1, 160-168DOI: (10.1016/j.euo.2018.03.006) Copyright © 2018 European Association of Urology Terms and Conditions